The National Kidney Foundation Innovation Fund, the philanthropic impact investment program of NKF, has made its latest investment in MediGO, a first-of-its-kind healthcare supply chain technology company focused on improving equity, access, and transparency in the organ donation and transplant industry.
MediGO is digitally transforming kidney donation and transplant operations to increase access to lifesaving organs and tissue. NKF funding will assist MediGO in the development, implementation, and overhaul of the kidney transplantation supply chain through advances in technology.
The supply chain that fuels the organ donation and transplantation industry is a complex ecosystem with medical teams, support staff, pilots, couriers, and families all working together to save a life with each precious organ. Many steps make up the supply chain, and historically, it has lacked end-to-end visibility, agility and equity. Lifesaving organs have been tracked with a system of texts, calls, and paper trails leading to waste and inefficiency in the system.
Launched in 2021, the NKF Innovation Fund works to accelerate funding, development, and commercialization of therapies that kidney patients need and deserve. The fund invests in early to mid-stage companies that are developing innovative, patient-centric kidney therapies. Read more.
